Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2000

01-12-2000 | Paper Report

ER variants in breast cancer

Author: Valerie Speirs

Published in: Breast Cancer Research | Issue 1/2000

Login to get access

Excerpt

ER is expressed in approximately 60% of all breast cancers. It is an independent prognostic factor upon which decisions on whether to give hormonal therapy are based. Two forms of ER are known to exist, the original ER, now renamed ERα, and the more recently discovered, ERβ. The ERα gene consists of eight exons from which splice variants can arise due to alternative processing. The relative frequency of such variants in breast cancer progression is, however, unclear. …
Literature
1.
Anandappa SY, Sibson R, Platt-Higgins A, Winstanley JHR, Rudland PS, Barraclough R: Variant estrogen receptor α mRNAs in human breast cancer specimens. Int J Cancer. 2000, 88: 209-216.CrossRefPubMed
Metadata
Title
ER variants in breast cancer
Author
Valerie Speirs
Publication date
01-12-2000
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2000
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr-2000-66713

Other articles of this Issue 1/2000

Breast Cancer Research 1/2000 Go to the issue

Paper Report

Marker of increased cancer risk in benign breast disease

Paper Report

Microdissection and microarrays

Paper Report

Multigene expression patterns predict metastatic behavior

Paper Report

An in vitrobreast cell immortalisation assay

Paper Report

Breast cancer protection: hormonal priming via p53?

Paper Report

ER? expression seems important in preinvasive cancers
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits